Hypertension

Latest News

Updated Pediatric Hypertension Guidelines Improve Prediction of Future CV Outcomes

The 2017 guidelines identified a group of children whose CV risk may have been underestimated using older guidelines.

Normalizing BP in Elderly With Prior CV Event History May Increase Mortality

Normalized blood pressure is associated with an increased risk for all-cause mortality for older adults during hypertension treatment.

Lower SBP Linked to Cognitive Decline in Older Adults Taking Antihypertensives

Elderly individuals treated with antihypertensive medications and have a SBP of ≥130 mm Hg display less cognitive decline after 1 year compared with individuals with an SBP of <130 mm Hg.

FDA Provides List of Nitrosamine-Free ARB Medications

The FDA has released a list of 40 ARBs that do not contain any known nitrosamine impurities.

Coronary Artery Calcium Score Reliably Risk Stratifies Adults With Hypertension

Coronary artery calcium scoring can risk-stratify patients with hypertension, including those who are SPRINT eligible and can recategorize risk around the atherosclerotic CVD 10% threshold.

Catheter-Based Renal Sympathetic Denervation Effectively Lowers BP

Renal sympathetic denervation significantly reduced blood pressure compared with shame procedures.

Endovascular Renal Denervation Results in Sustained BP Reduction

The benefits of reduced blood pressure following renal denervation surgery are maintained for at least six months.

Does Ranolazine Potentiate the Effects of ACE Inhibitors, Angiotensin Receptor Blockers?

Ranolazine potentiates the effects associated with ACE inhibitors, as well as angiotensin receptor blockers.

Clinical Outcomes Compared With Generics, Brand-Name Drugs for Chronic Conditions

An analysis found comparable clinical outcomes among patients who initiated generics vs those who were treated with brand-name drugs for chronic conditions.

FDA Approves New Valsartan Product Following Major Recall

The FDA has approved a new generic version of Diovan (Novartis) that does not contain NDMA or NDEA, 2 potentially carcinogenic impurities identified in several recalled valsartan products.